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What does this paper add to the literature? 
This observational study in 103 patients reports a significant association between 18F FDG-
PETCT derived measures of tumour metabolism and systemic inflammation in patients with 
recurrent colorectal cancer.  It may be that tumour metabolism is one of the driving 
mechanisms behind host systemic inflammation in solid tumours. 
 
Abstract 
Aim 
 
18
F FDG-PETCT derived markers of tumour metabolism have been reported to have 
prognostic significance in a variety of tumours.  Host inflammation is also recognised to have 
prognostic significance.  The aim of the present study was to investigate the relationship 
between these markers and host systemic inflammation in patients undergoing elective 
surgery for colorectal cancer. 
Methods 
Patients with histologically confirmed colorectal cancer, who underwent elective surgery 
between 2008 and 2015, who also underwent 
18
F FDG-PETCT, at a single centre were 
included (n =103). Neutrophil lymphocyte ratio (NLR) and modified Glasgow Prognostic 
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Score (mGPS) were derived from routine blood tests. The maximum standardised uptake 
(SUVmax), peak standardised uptake (SUVpeak), metabolic tumour volume (MTV) and total 
lesion glycolysis (TLG) were measured.  
 
Results 
There was no association between 18F FDG-PETCT measures of tumour metabolism and 
systemic inflammation in the 33 patients who underwent preoperative imaging.  Of the 70 
patients with recurrent disease who underwent 
18
F FDG-PETCT during follow up, patients 
with NLR ≥5 had a significantly higher SUVmax (20 vs 7, p=0.002), SUVpeak (14 vs 5, 
p<0.001), MTV (29g vs 2g, p=0.001) and TLG (338g vs 9g, p<0.001). Similarly, patients 
with an mGPS of 1-2 at the time of 
18
F FDG-PETCT had a significantly higher median 
SUVmax (11 vs 6, p=0.048), SUVpeak (8 vs 4, p=0.046), MTV (13mL vs 2mL, p=0.005) 
and TLG (146g vs 10g, p=0.004).   
 
Conclusions 
The present study reports a direct association between 
18
F FDG-PETCT derived measures of 
tumour metabolism and systemic inflammation in patients with recurrent colorectal cancer.  
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Introduction 
 
Colorectal cancer is one of the most common malignancies in the Western world [1]. It is 
now well understood that the host systemic inflammatory response, evaluated using the 
modified Glasgow Prognostic Score (mGPS) [2], and neutrophil lymphocyte ratio (NLR) [3], 
is an important prognostic factor in patients with either primary operable or advanced 
inoperable cancer. However, the nature of the link between the systemic inflammatory 
response and the primary or secondary tumour is poorly understood. 
  Fluorine-18-fluorodeoxyglucose positron emission tomography-computed 
tomography (
18
F FDG-PETCT) is a nuclear medicine imaging technique based on the relative 
uptake of glucose.  The radioactive tracer is taken up by cells as glucose would normally be, 
and the positrons emitted are detected by the PET scanner.  The spatial distribution of 
metabolic activity derived from PET is co-registered with CT to provide accurate anatomical 
location of increased glucose uptake.  It can be used in staging, monitoring response to 
neoadjuvant therapy, and detecting loco-regional recurrence or metastases in colorectal 
cancer patients [4-5].
 18
F FDG-PETCT measures the net glucose uptake in tumours and 
provides objective data on tumour glucose metabolism.  In patients with colorectal cancer, 
higher glucose metabolism, as determined by 
18
F FDG-PETCT, has been associated with 
markers of tumour proliferation [6-7], lower likelihood of down staging following 
neoadjuvant chemoradiotherapy [8], and long term survival [9-11].   
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More recently, 
18
F FDG-PETCT parameters  have been shown to be associated with 
long term anti-inflammatory use in patients with colorectal cancer [12], and with preoperative 
systemic inflammation in patients with lung cancer [13]. Based on these recent findings, we 
hypothesised that the host systemic inflammatory response may be associated with tumour 
metabolism.  
Therefore, the aim of the present study was to investigate the relationship between the 
18
F FDG-PETCT derived markers of tumour metabolism, in both primary and recurrent 
colorectal cancer, and host systemic inflammation in patients who underwent surgery for 
colorectal cancer. 
 
Patients and methods 
Patients: 
Patients with histologically confirmed colorectal cancer, who underwent elective, potentially 
curative surgery between February 2008 and April 2015, who also underwent 
18
F FDG-
PETCT during their treatment, either prior to surgery, or as part of their follow up after 
surgery, at a single centre were included in the study.  Patients had routine blood sampling 
including a full blood count (FBC), serum CRP and albumin concentration at the time of 
18
F 
FDG-PETCT. 
It was found that 
18
F FDG-PETCT scans had been performed in two groups of 
patients.  The first group were patients imaged during preoperative staging prior to surgery, in 
whom 
18
F FDG-PETCT parameters were measured from the primary colonic or rectal lesion.  
The second group were patients imaged during postoperative follow up, at the request of the 
colorectal multidisciplinary meeting (MDT), and found to have probable recurrent disease in 
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CT and/or MRI imaging, and in whom 
18
F FDG-PETCT parameters were measured from the 
recurrent or dominant metastatic lesion.  The  colorectal MDT based 
18
F FDG-PETCT 
requests on prior clinical imaging and the presence of a systemic inflammatory response was 
not considered a barrier to 
18
F FDG-PETCT.  No patient who had undergone preoperative 
18
F 
FDG-PETCT subsequently underwent postoperative 
18
F FDG-PETCT.  All 
18
F FDG-PETCT 
scans were analysed and reported by consultant nuclear medicine physicians. 
Patients were offered adjuvant chemotherapy following surgery by a specialist 
colorectal multidisciplinary team on the basis of postoperative histopathology.  In most cases, 
those patients who were found to be TNM stage II with adverse prognostic features [14], or 
higher, were offered 5-FU containing adjuvant treatment following consideration of 
comorbidities.  This retrospective observational study was approved by the West of Scotland 
Research Ethics Committee. 
 
Methods: 
Data was collected prospectively in a database, anonymised, and subsequently analysed. 
18
F 
FDG-PETCT images were retrospectively analysed by a consultant nuclear medicine 
physician blind to the clinical outcomes, mGPS or NLR. Recorded information included 
patient demographics, clinicopathological, operative and radiological (
18
F FDG-PETCT) 
data. Recorded 
18
F FDG-PETCT parameters included maximum standardised uptake value 
(SUVmax), peak standardised uptake value (SUVpeak), metabolic tumour volume and total 
lesion glycolysis.   Serum concentrations of CRP (mg/L) were measured using an 
autoanalyzer (Architect; Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit 
of 0.2 mg/L as was serum albumin (normal range 35-50g/L).    The neutrophil lymphocyte 
ratio was calculated for each patient for whom neutrophil and lymphocyte counts were 
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available [3]. The modified Glasgow Prognostic Score (mGPS) was calculated in patients for 
whom serum CRP and albumin concentrations were available [2].   
 
18
F FDG-PETCT: 
18
F FDG-PETCT scanning was performed according to our department standard procedures 
based on the EANM guidelines [15]. Patients were fasted for at least 6 hours before and 1 
hour after the IV injection of 400MBq 
18
F-FDG. Blood glucose levels were measured before 
18
F-FDG injection to ensure concentrations <11mmol/l. 
18
F-FDG PETCT scanning was 
performed on one of the two multimodality PETCT scanners (Discovery-690 or 710, General 
Electric System, Milwaukee, WI, USA). Unenhanced CT images were acquired using a 
120kV automatic mA modulation range of 15-240mAs. The torso CT covered from the skull 
base to the mid-thigh, with reconstructions performed at 2.5 mm increments. This was 
followed by PET images, encompassing the same transverse field of view as the CT. PET 
acquisition time was 3-4 minutes per bed position. PET attenuation correction was based on 
the CT data and images were corrected for scatter and iteratively reconstructed using Time of 
Flight and SharpIR on a 192x192 matrix. 
PETCT images were analysed on GE Advantage Workstation using a SUVmax of 7g/ml 
threshold level to view the PET images. SUV max, TLG and MTV were obtained from 3D 
isocontour at 42% of the maximal pixel value (VOL42). PETCT data were measured from 
the region of interest (ROI) placed over the dominant sites (Primary tumour site in pre-
operative staging cases, and the local recurrent sites or metastatic sites in post-operative 
suspected relapse cases).  
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Statistical Analysis: 
Significant differences were found in the 
18
F FDG-PETCT parameters between patients who 
underwent 
18
F FDG-PETCT preoperatively or during the postoperative follow up period, 
therefore subgroup analysis was performed in those patients who underwent 
18
F FDG-
PETCT during their follow up period. Categorical data were compared using the Chi square 
test and Chi square for linear association where appropriate.  Continuous data were displayed 
as medians and ranges. These continuous data were compared using the Mann-Whitney U 
test.   
Survival analysis was performed only in the group who underwent 
18
F FDG-PETCT 
during postoperative follow up.  Univariate and multivariate survival data were analysed 
using Cox’s proportional hazards model.  For survival analysis of 18F FDG-PETCT 
parameters, patients were grouped according by whether their values were above or below the 
median value.  Variables associated with disease specific survival at a significance level of p 
<0.1 on univariate analysis were included in multivariate modelling using backward 
conditional regression where a two sided p value <0.05 was considered statistically 
significant.  Disease specific survival was defined as time from date of 
18
F FDG-PETCT to 
date of cancer specific death.   
Statistical analyses were performed using IBM SPSS version 22 for Windows 
(Chicago, IL, USA).  Two tailed p values <0.05 were considered statistically significant.           
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Results 
 
Patients: 
In total, 103 patients were included in the study (Table 1). The majority were male (57, 55%), 
over 65 (59, 57%) and with node negative disease (53, 51%). Thirty three (32%)  patients 
underwent 
18
F FDG-PETCT during pre-operative staging while, 70 (68%)  patients 
underwent 
18
F FDG-PETCT for suspected recurrence during follow up after elective surgery 
for colorectal cancer.  Of the 33 patients who underwent 
18
F FDG-PETCT during 
preoperative staging, 15 (45%) had undergone prior neoadjuvant chemoradiotherapy.  Of the 
70 patients who underwent 
18
F FDG-PETCT during postoperative follow up, 28 (40%)  
received adjuvant chemotherapy prior to
18
F FDG-PETCT. 
Comparison of patients undergoing 
18
F FDG-PETCT during preoperative staging and during 
postoperative follow up: 
Primary lesions measured in patients who underwent 
18
F FDG-PETCT preoperatively had a 
significantly higher SUVmax (17 vs 7, p=<0.001), higher SUVpeak (10 vs 5, p=<0.001), a 
higher MTV (8mL vs 2mL, p=0.001) and higher TLG (90g vs 10g, p=<0.001) than recurrent 
lesions measured in patients during postoperative follow up (Table 1). A significantly higher 
proportion of patients who underwent 
18
F FDG-PETCT during preoperative staging had 
rectal cancer, when compared to those who underwent 
18
F FDG-PETCT during follow up 
(52% vs. 29%, p=0.024).  However, there were no other statistically significant associations 
with demographic variables, including sex (p=0.754), age (p=0.415), BMI (p=0.627), ASA 
grade (p=0.480), smoking status (p=0.921), or the pathology of the primary resected lesion, 
including T stage (p=0.569), N stage (p=0.852), differentiation (p=0.110), or venous invasion 
p=0.993).   
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Association between 
18
F FDG-PETCT and systemic inflammation at the time of preoperative 
staging: 
Of the 33 patients who underwent 
18
F FDG-PETCT preoperatively and had their primary 
lesion assessed, there was no association between clinicopathological variables, systemic 
inflammation (mGPS and NLR), and SUVmax, SUVpeak, MTV or TLG. 
 
Association between 
18
F FDG-PETCT and NLR in patients with suspected disease 
recurrence: 
Of the 70 patients who underwent 
18
F FDG-PETCT during follow up after surgery, 68 
patients had their NLR measured prior to 
18
F FDG-PETCT (Table 2). Patients with NLR ≥5 
at the time of 
18
F FDG-PETCT (n=5) had a significantly higher SUVmax (20 vs 7, p=0.002), 
SUVpeak (14 vs 4, p<0.001), MTV (29mL vs 2mL, p=0.001) and TLG (338g vs 9g, 
p<0.001) when compared to those patients with NLR<5.  However, NLR was not associated 
with demographic variables including sex (p=0.794), age (p=0.116), BMI (p=0.595), ASA 
grade (p=0.869), smoking status (p=0.121), the pathology of the primary resected lesion, 
including tumour location (p=0.602), T stage (p=0.282), N stage (p=0.247), differentiation 
(p=0.735) and venous invasion (p=0.199), or adjuvant chemotherapy prior to 
18
F FDG-
PETCT (p=0.059).  Furthermore, when analysed at an NLR threshold of 3 (Malietzis et al. 
2014), there was no association found between NLR and 
18
F FDG-PETCT parameters, 
demographic variables, pathology of primary lesion, or adjuvant chemotherapy.  
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Association between 
18
F FDG-PETCT and mGPS in patients with suspected disease 
recurrence: 
Of the 70 patients who underwent 
18
F FDG-PETCT during follow up after surgery, 59 
patients had an mGPS measured prior to 18FDG-PETCT (Table 3). Patients with an mGPS of 
1-2 at the time of 
18
F FDG-PETCT had a significantly higher SUVmax (11 vs 6, p=0.048), 
SUVpeak (8 vs 4, p=0.046), MTV (13mL vs 2mL, p=0.005) and TLG (146g vs 10g, 
p=0.004) when compared to those patients with mGPS of 0.  However, mGPS was not 
associated with demographic variables including sex (p=0.535), age (p=0.727), BMI 
(p=0.160), ASA grade (p=0.402), smoking status (p=0.989), the pathology of the primary 
resected lesion, including tumour location (p=0.545), T stage (p=0.822), N stage (p=0.871), 
differentiation (p=0.183) and venous invasion (p=0.378), or adjuvant chemotherapy prior to 
18
F FDG-PETCT (p=0.458).” 
 
Survival: 
Of the 70 patients who underwent 
18
F FDG-PETCT during postoperative follow up, the 
median follow up period for patients alive at the time of their censoring was 25 months 
(range 8 - 78 months).  There were 19 cancer related deaths and 4 non-cancer related deaths.  
At univariate analysis (Table 4) there was an association between N stage (HR 4.78, 95% CI 
1.58-14.43, p=0.006),  SUV peak (HR 3.01, 95% CI 1.21-7.48, p=0.018), and TLG (HR 2.51, 
95% CI 1.00-6.28, p=0.049) with disease specific survival at a significance level of p<0.1  At 
multivariate analysis, only N stage (HR 4.05, 95% CI 1.32-12.41, p=0.014) remained 
independently prognostic. 
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Discussion 
 
The results of the present study show that 
18
F FDG-PETCT derived markers of tumour 
metabolism in recurrent lesions are associated with systemic inflammation following elective 
surgery for colorectal cancer. 
In the present study it was of interest that when compared to those patients who 
underwent 
18
F FDG-PETCT preoperatively, patients who underwent 
18
F FDG-PETCT during 
follow up after elective surgery for colorectal cancer were more likely to have a lower 
SUVmax, SUVpeak, MTV and TLG. In the former, patients parameters were measured from 
the primary lesion. In contrast, in the latter  parameters were measured from the dominant 
recurrent local or metastatic lesion. This may suggest that metastatic or recurrent lesions are 
metabolically less active in comparison to primary lesions.  It may be that primary lesions are 
more established in terms of their supporting stroma and neovascularisation than locally 
recurrent or metastatic lesions. Alternatively, adjuvant chemotherapy may play a role in 
diminishing the metabolism of metastatic or recurrent lesions, although the proportion of 
patients receiving systemic treatment prior to 
18
F FDG-PETCT in each cohort was similar.  
However, the size of the compared primary and recurrent lesions was not formally measured.  
The significant difference in MTV between primary and secondary lesions suggests that the 
primary lesions were on average larger, which might itself be a confounding factor.  
Nevertheless, to our knowledge, no previous study has compared 
18
F FDG-PETCT measures 
of tumour metabolism in primary and metastatic or recurrent lesions in patients with 
colorectal cancer. 
 The results of the present study suggest an association between systemic 
inflammation and 
18
F FDG-PETCT derived measures of tumour metabolism in patients with 
recurrent colorectal cancer.
 18
F FDG-PETCT has been used to assess disease response and 
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has been reported to be prognostic in patients with colorectal cancer [8-11], however very 
little prior work has been carried out in the context of systemic inflammatory response [13, 
16].  To the author’s knowledge, this is the first study directly examining the relationship 
between 
18
F FDG-PETCT parameters and measures of systemic inflammation in colorectal 
cancer.   
The presence of systemic inflammation has been reported to be a negative prognostic 
factor in a variety of solid tumour types including colorectal cancer [2].  Indeed, 
inflammation is now considered one of the hallmarks of cancer [17].  Furthermore, some 
consider inflammation to be a requirement for recurrence and metastasis.  Therefore it is of 
great interest that the present study suggests that the metabolic activity of recurrent lesions is 
linked to host systemic inflammation.  If this suggested direct relationship between the 
18
F 
FDG-PETCT derived measures of tumour metabolism and the systemic inflammatory 
response were to be confirmed then this would shed new insight into the relationship between 
tumour and host processes.   
18
F FDG-PETCT provides an estimate of glucose uptake of the entire lesion, which 
includes both cancer cells and the tumour microenvironment.  The tumour microenvironment, 
composed of blood vessels, stroma and immune cells support tumour cell growth and spread 
and is an important factor in tumour development and outcomes in a number of solid organ 
cancers [17-18]. The mechanism by which the tumour stroma facilitates tumour progression 
has not been fully elucidated, however key theories include factors from the stroma 
influencing local inflammation, tumour pH, and tumour metabolism.  In addition to the 
proportion of stroma, the local inflammatory cell infiltrate is recognised to be prognostic in 
colorectal cancer [19].  It is possible that cytokines and other factors produced by the local 
inflammatory cells, which are related to local metabolic processes, also influence the host 
systemic inflammatory response [20]. 
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Furthermore, a recent observational study in patients with gastric cancer reported that 
FDG uptake by bone marrow was an independent prognostic factor, and that bone marrow 
PETCT parameters in these patients were associated with markers of the systemic 
inflammatory response including NLR and CRP [21].  This work by Lee and colleagues [21] 
may suggest that circulating inflammatory cells, as part of the systemic inflammatory 
response, have a direct effect on tumour metabolism. This observation is worthy of further 
investigation in patients with colorectal cancer. 
In the present study, a significantly higher proportion of patients who underwent 
18
F 
FDG-PETCT during preoperative staging had rectal cancer, when compared to those who 
underwent 
18
F FDG-PETCT during follow up.  However, when a subgroup analysis was 
performed including only patients with colon cancer, similarly significant differences 
between primary and recurrent lesions, and 
18
F FDG-PETCT derived markers of tumour 
metabolism were present.   
No patient who had undergone preoperative 
18
F FDG-PETCT subsequently 
underwent postoperative 
18
F FDG-PETCT.  Therefore within the present study it is not 
possible to comment on any relationship which might exist between the derived markers of 
tumour metabolism in primary lesions and then in subsequent recurrence within the same 
patient.  However, the demographic, clinical, and gross pathological features were similar 
across the two groups of patients. 
Given the significant relationship between the presence of systemic inflammation and 
18
F FDG-PETCT derived measures of tumour metabolism in recurrent lesions, it might be 
suggested that patients found to have a systemic inflammatory response during follow up 
undergo 
18
F FDG-PETCT if standard follow up CT and/or MRI imaging does not 
demonstrate any obvious recurrent disease.  Furthermore, the results of the present study 
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suggest that the addition of anti-inflammatory drugs to chemotherapy regimens in patients 
found to be systemically inflamed during follow up may be of benefit by modulating tumour 
metabolism.  Such changes to post surgical follow up and oncological treatments require 
evaluation in the context of a prospective trial with additional translational endpoints. 
The main limitation of the present study was the relatively small number of patients, 
in particular those undergoing 
18
F FDG-PETCT preoperatively.  This prevented meaningful 
survival analysis with regard to preoperative 
18
F FDG-PETCT parameters.  Within the 
patients with suspected disease recurrence, the follow up period for the cohort is at present 
relative immature with a small number of events therefore it is likely that both systemic 
inflammation and 
18
F FDG-PETCT derived measures of tumour metabolism have prognostic 
importance in this group of patients.  In addition, due to the retrospective analysis of PETCT 
scans, no clinical data were available regarding potentially acute illness that may have 
confounded these scans.  Furthermore, the retrospective nature of the study meant that not all 
patients had their CRP and white cell count measured at the time of 
18
F FDG-PETCT.  The 
methodology meant only lesion MTV and TLG, and not that of the whole body was 
measured. 
 In conclusion, the present study reports a significant association between 
18
F FDG-
PETCT measure of tumour metabolism in locally recurrent and metastatic colorectal cancer, 
and systemic inflammation.  It may be that tumour metabolism is one the driving mechanisms 
behind host systemic inflammation in solid tumours.  Further work is required to fully 
characterise the relationship between the systemic inflammatory response and 
18
F FDG-
PETCT findings in patients with colorectal cancer.  However, the present results suggest that 
the systemic inflammatory response and 
18
F FDG-PETCT are complimentary in both the 
staging and follow up of patients with colorectal cancer.   
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Tables and footnotes 
Table 1: Relationship between the
18
F FDG-PETCT timing and clinicopathological variables in 
patients undergoing elective surgery for colorectal cancer (n=103) 
 
Characteristic All 
18
F FDG-PETCT P 
Primary lesions 
(n=33) 
Recurrent lesions 
(n=70) 
 
Demographic     
Sex (male/female) 57/46 19/14 38/32 0.754 
Age (<65/65-74/>74) 44/46/13 11/17/5 33/29/8 0.415 
BMI (median/range)/ kg/m2 26(14.5-45) 26.5(17-45) 26(14.5-43) 0.627 
ASA Grade (1/2/3/4) 27/42/30/3 10/10/12/1 17/32/18/2 0.480 
Smoking (no/ex/current) 42/40/19 13/14/6 29/26/13 0.921 
     
Primary lesion pathology     
Site (colon/recutm) 66/37 16/17 50/20 0.024 
T stage (T1-T2/T3-T4) 19/83 7/25 12/58 0.569 
N stage (N0/N1-N2) 53/47 16/15 37/32 0.852 
Differentiation 
(poor/moderate/well) 
11/87/4 4/25/3 7/62/1 0.110 
Venous invasion (yes/no) 67/35 21/11 46/24 0.993 
Adjuvant chemotherapy before 
18F FDG-PETCT (yes/no) 
28/75 0/33 28/42 - 
     
18
F FDG-PETCT parameters     
SUVmax (median/range) 11(0-35) 17 (0-35) 7 (0-34) <0.001 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
SUVpeak (median/range) 8 (0-29) 10(0-29) 5 (0-23) <0.001 
MTV (median/range)/mL 4 (0-311) 8 (0-48) 2(0-311) 0.001 
TLG (median/range)/g 28 (0-3124) 90 (0-503) 10 (0-3124) <0.001 
     
Systemic inflammation     
NLR(<5/≥5) 90/11 27/6 63/5 0.101 
mGPS (0/1-2) 70/22 27/6 43/16 0.335 
 
PET positron emission tomography, BMI body mass index, ASA American Society of Anesthesiology, mGPS 
modified Glasgow Prognositc Score, NLR Neutrophil Leukocyte Ratio, MTV metabolic tumour volume, 
SUVmax maximum standardised uptake value, SUVpeak peak standardised uptake value, TLG total lesion 
glycolysis 
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Table 2: Relationship between NLR and clinicopathological variables in patients who underwent 
18
F 
FDG-PETCT during follow up after elective surgery for colorectal cancer (n=68) 
 
Characteristic All NLR p 
<5 (n=63) ≥5 (n=5)  
Demographic     
Sex (male/female) 37/31 34/29 3/2 0.794 
Age (<65/65-74/>74) 32/28/8 30/27/6 2/1/2 0.116 
BMI (median/range)/ kg/m2 26(14.5-43) 26(14.5-43) 24.7(20-36) 0.595 
ASA Grade (1/2/3/4) 16/32/17/2 15/30/15/2 1/2/2/0 0.869 
Smoking (no/ex/current) 29/25/12 28/21/12 1/4/0 0.121 
     
Primary lesion pathology     
Site (colon/rectum) 50/18 47/16 3/2 0.602 
T stage (T1-T2/T3-T4) 12/56 12/51 0/5 0.282 
N stage (N0/N1-N2) 37/30 33/29 4/1 0.247 
Differentiation 
(poor/moderate/well) 
7/60/1 6/56/1 1/4/0 0.735 
Venous invasion (yes/no) 23/45 20/43 3/2 0.199 
Adjuvant chemotherapy before 
18
F FDG-PETCT (yes/no) 
41/27 36/27 5/0 0.059 
     
18
F FDG-PETCT parameters     
SUVmax (median/range) 7(0-34) 7(0-34) 20 (16-29) 0.002 
SUVpeak (median/range) 5 (0-23) 5 (0-23) 14(13-23) <0.001 
MTV (median/range)/mL 2(0-311) 2(0-311) 29 (9-261) 0.001 
TLG (median/range)/g 10 (0-3124) 9 (0-1962) 338 (95-3124) <0.001 
 
PET positron emission tomography, BMI body mass index, ASA American Society of Anesthesiology, NLR 
Neutrophil Leukocyte Ratio, MTV metabolic tumour volume, SUVmax maximum standardised uptake value, 
SUVpeak peak standardised uptake value, TLG total lesion glycolysis 
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Table 3: Relationship between mGPS and clinicopathological variables in patients who underwent 
18
F 
FDG-PETCT during follow up after elective surgery for colorectal cancer (n=59) 
 
Characteristic All mGPS P 
0 (n=43) 1-2 (n=16)  
Demographic     
Sex (male/female) 29/30 23/20 6/10 0.535 
Age (<65/65-74/>74) 25/27/7 17/21/5 8/6/2 0.727 
BMI (median/range)/ kg/m2 26(14.5-43) 26(14.5-37) 24(20-38) 0.160 
ASA Grade (1/2/3/4) 13/27/16/2 10/18/14/1 3/9/2/1 0.402 
Smoking (no/ex/current) 23/24/11 17/18/8 6/6/3 0.989 
     
Primary lesion pathology     
Site (colon/rectum) 40/19 28/15 12/4 0.545 
T stage (T1-T2/T3-T4) 10/49 7/36 3/13 0.822 
N stage (N0/N1-N2) 28/30 20/22 8/8 0.871 
Differentiation 
(poor/moderate/well) 
6/53/0 3/40/0 3/13/0 0.183 
Venous invasion (yes/no) 20/39 16/27 4/12 0.378 
Adjuvant chemotherapy before 
18
F FDG-PETCT (yes/no) 
23/36 18/25 5/11 0.458 
     
18
F FDG-PETCT parameters     
SUVmax (median/range) 7(0-34.3) 6(0-31) 11 (0-34) 0.048 
SUVpeak (median/range) 5 (0-23) 4 (0-22) 8 (0-23) 0.046 
MTV (median/range)/mL 2(0-311) 2(0-32) 13(0-311) 0.005 
TLG (median/range)/g 10 (0-3124) 8 (0-271) 146(0-3124) 0.004 
 
PET positron emission tomography, BMI body mass index, ASA American Society of Anesthesiology, mGPS 
modified Glasgow Prognositc Score, MTV metabolic tumour volume, SUVmax maximum standardised uptake 
value, SUVpeak peak standardised uptake value, TLG total lesion glycolysis 
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Table 4: Impact of systemic inflammation and 
18
F FDG-PETCT derived measures of tumour 
metabolism on disease specific survival in patients with recurrent disease following surgery 
for colorectal cancer, univariate and multivariate survival analysis (n=70) 
 
Variable Univariate HR (95% CI) P Multivariate HR (95% 
CI) 
P 
Male Sex 1.57 (0.62-3.99) 0.341 - - 
Age 1.28 (0.64-2.55) 0.481 - - 
BMI 0.74 (0.47-1.17) 0.199 - - 
ASA 0.67 (0.35-1.28) 0.223 - - 
Smoking 1.27 (0.71-2.30) 0.442 - - 
Rectal 1.25 (0.49-3.18) 0.640 - - 
T stage 1.94 (0.45-8.40) 0.376 - - 
N stage  4.78 (1.58-14.43) 0.006 4.05 (1.32-12.41) 0.014 
Differentiation 0.78 (0.10-5.98) 0.811 - - 
Venous invasion 2.11 (0.70-6.37) 0.185 - - 
mGPS 1.93 (0.71-5.44) 0. 193 - - 
NLR 3.37 (0.73-15.57) 0.120 - - 
SUVmax 2.02 (0.82-4.98) 0.128 - - 
SUVpeak 3.01 (1.21-7.48) 0.018 2.39 (0.95-5.99) 0.064 
MTV 1.68 (0.66-4.22) 0.275 - - 
TLG 2.51 (1.00-6.28) 0.049 - 0.720 
 
HR Hazard Ratio, CI Confidence Interval, BMI body mass index, ASA American Society of Anesthesiology,, 
mGPS modified Glasgow Prognostic Score, NLR Neutrophil lymphocyte ratio, MTV metabolic tumour volume, 
SUVmax maximum standardised uptake value, SUVpeak peak standardised uptake value, TLG total lesion 
glycolysis  
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Figures and Legends 
Figure 1: (A) Initial follow up CT imaging followed by (B) 
18
F FDG-PET, (C) CT and (D) 
18
F FDG-PETCT in a patient with locoregional recurrence (long arrow).  Short arrow denotes 
physiological bladder activity. 
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Figure 2: (A) Initial follow up CT imaging followed by (B) 
18
F FDG-PET, (C) CT and (D) 
18
F FDG-PETCT in a patient with liver metastases (arrowed).  Long arrow denotes dominant 
metastasis. 
 
 
 
